Gilead Sciences acquired Pharmasset, Inc. for ~$11.05 billion, a transaction announced in January 2012.
Acquired the hepatitis C drug developer to obtain sofosbuvir (later Sovaldi/Harvoni), transforming Gilead into the leader in HCV cure therapy. Purchased via a $137.00-per-share cash tender offer and merger.
Acquired the hepatitis C drug developer to obtain sofosbuvir (later Sovaldi/Harvoni), transforming Gilead into the leader in HCV cure therapy. Purchased via a $137.00-per-share cash tender offer and merger.
Advisory firms were not disclosed for this transaction.